How many investments has Versant Ventures made?

Versant Ventures has 107 tracked investments, 16 of which have exited, including 9 dated in the last 24 months.

What stage does Versant Ventures invest at?

Versant Ventures invests at the Seed, Series A, Series B, Series C, Late Stage stages.

What is Versant Ventures's typical check size?

Versant Ventures typically writes checks of $250K – $5M.

What sectors does Versant Ventures focus on?

Versant Ventures focuses on Biotech, Healthtech.

Where is Versant Ventures located?

Versant Ventures is headquartered in San Francisco, US.

Does Versant Ventures lead rounds?

Versant Ventures typically participates in rounds rather than leading them.

Who does Versant Ventures co-invest with?

Versant Ventures most often shares deals with GV (Google Ventures), New Enterprise Associates (NEA), RA Capital, among 52 tracked co-investors.

Versant Ventures

Venture capitaloperating company · company profile

San Francisco · Seed–Late Stage · 55 people tracked

Also known as Versant Capital Management, Inc. · VERSANT VENTURE MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Versant Ventures

Paths you didn't know you had: your email and LinkedIn already hold routes to the Versant Ventures team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Versant Ventures focuses on building novel biotechnology companies, pairing academic founders with its in-house Discovery Engines—teams of multidisciplinary scientists operating state-of-the-art laboratory facilities. This model emphasizes translating scientific discoveries from academia into company creation within the biotech sector.

Invests inBiotech Healthtech Canada Europe North America San Francisco Switzerland United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Check

$250K – $5M

San Francisco, CA, US

Leads rounds

Follows

Instruments

Equity

Founded

1999

Last 12 months

4 investments

AUM

$5.5B

VC funds

Tracked investments

107

Unicorns

IPOs

Acquisitions

Team · 55 people

from the firm's website & curated & public directories

Brad Bolzon· Chairman, Managing Director· Canada

Brad Bolzon merges 13 years of senior R&D and business development at Eli Lilly and Roche with architecting cross-border company creation—co-founding Inception Sciences, chairing CRISPR Therapeutics, and building multi-hub presence.

brad@versantventures.com

Bradley Bolzon· General Partner

Charles M. Warden· General Partner

Rebecca Robertson· General Partner

Alex Mayweg· Managing Director· Basel, Switzerlandin 𝕏

Managing Director at Versant and head of Ridgeline Therapeutics, Versant's Basel-based Discovery Engine, with deep experience in drug discovery and medicinal chemistry. He previously served as global head of chemistry at Roche over a 14-year career and holds a Ph.D. in organic chemistry from Oxford, with post-doctoral training at Stanford and an undergraduate degree from Imperial College London.

amayweg@versantventures.com

Carlo Rizzuto· Managing Director· New York, New Yorkin 𝕏

Carlo Rizzuto, a PhD virologist-turned-VC who pioneered and championed epitranscriptomics and backed Gotham Therapeutics early, is a hands-on builder who often serves as acting CEO/CBO to create first-wave biology companies.

crizzuto@versantventures.com

Clare Ozawa· Managing Director· San Diego, Californiain

Clare Ozawa combines a Stanford Ph.D. with experience as COO/CBO at Inception Sciences, leads San Diego–Bay Area investments and sits on boards of Capsida, Lycia, Gate Bioscience and 858 Therapeutics.

clare@versantventures.com

Jerel Davis· Managing Director· Vancouver, BCin 𝕏

Jerel Davis is a PhD-trained life scientist and Vancouver-based investor who builds biotechs from scratch via pharma partnerships—co-founding BlueRock with Bayer ($225M) and designing ventures with acquirers in mind.

jdavis@versantventures.com

Markus Enzelberger· Partner· Munich, Germanyin

Markus is a Versant partner in Basel who helps launch new companies from the firm's Ridgeline Discovery Engine. A drug discovery and protein engineering expert, he previously served as CSO and management board member of MorphoSys, which he joined in 2002, and holds a Ph.D. from the Technical University of Stuttgart.

menzelberger@versantventures.com

Nigel Sheail· Partner· Basel, Switzerlandin

Nigel Sheail is a Versant partner based in Basel with over two decades of pharmaceutical leadership experience. He previously served as Global Head of M&A and Business Development & Licensing at Novartis, and held business development and M&A leadership roles at Bayer Healthcare and Roche.

nsheail@versantventures.com

Tom Woiwode· Managing Director· San Francisco, Californiain

Tom Woiwode is a PhD medicinal chemist with operating experience as CBO/COO who led IPOs/M&A exits including CRISPR Therapeutics and co-founds companies early with academics like Jim Wilson (iECURE).

twoiwode@versantventures.com

Camille Samuels· Managing Director· San Francisco Bay Areain

Ross Jaffe· Managing Director· Los Angeles, California, United Statesin

Barbara Lubash· Managing Director· Californiain

Barbara Lubash is Principal at Atlantic Pacific Advisors and has served as a board member and advisor for over 15 years across more than 10 corporate and nonprofit boards. She co-founded Versant Ventures, a firm focused on business-to-business tech-enabled health services and health technology companies, and previously held senior governance roles at California HealthCare Foundation, including Board Chair, where she oversaw the development of one of the first healthcare foundation Program Related Investment funds in the United States. Her experience spans health care operations, business innovation scaling, and strategic oversight functions including CEO succession, investment strategy, and audit and compliance committees.

Beckie Robertson· Managing Director· Palo Alto, California, United Statesin

Beckie Robertson is a Principal at Longridge Business Advisors. She has more than 30 years of experience in venture capital and operations, having worked as an engineer, entrepreneur, corporate executive, investor, board member, and business advisor. Her work has included advising management on business and technology strategy, financings, mergers and acquisitions, and organizational design.

Brian Atwood· Managing Director· Californiain

brian@versantventures.com

Don Milder· Managing Partner· Laguna Niguel, Californiain

Sam Colella· Managing Partner· Los Altos, California, United Statesin

Ariel Kantor· Principal

A scientist and company builder who joined Versant after serving as Chief Business Officer at ReCode Therapeutics and as an Entrepreneur-in-Residence at Oxford Science Enterprises, with prior experience as an investment banker at Evercore Partners. He holds a B.S. from Duke and a Ph.D. in Clinical Neuroscience from Oxford as a Rhodes Scholar, and has co-founded companies in genetic medicines and RNA biology.

Joel Drewry· Principal· Toronto, Ontarioin 𝕏

Principal in Versant's Toronto office who joined in 2014 and has been involved in the creation and launch of several companies in the US and Canada, with a focus on early company formation. Holds a Ph.D. in organic chemistry from the University of Toronto (2012).

jdrewry@versantventures.com

Mehmet Badur· Principal· San Diegoin

Mehmet Badur joined Versant in March 2022 as a Senior Associate and was promoted to Principal later that year, focusing on investments and company creation opportunities primarily on the West Coast. He previously worked at Rheos Medicines in business development and as a discovery scientist, and holds a PhD in Bioengineering from UC San Diego.

mbadur@versantventures.com

Michael Wong· Principal· Toronto, Canada

Principal at Versant focused on building and investing in new companies and driving pharma partnerships. Previously at Flagship Pioneering on the venture creation team, where he co-founded four biotech companies, and earlier co-founded and led ARCHITECHealth and Industry Link.

Nikita Sharma· Principal· Basel, Switzerlandin

Nikita Sharma joined Versant in February 2024 as a Principal based in Basel, supporting portfolio companies and new opportunities in Europe and North America. She previously served as M&A Director at Novartis, leading acquisitions of Chinook Therapeutics, Calypso Biotech and SanReno Therapeutics, and earlier held roles at Sandoz and Axalta. She holds an MBA from Symbiosis International University.

Kerrie Cohen· Principal· Americasin

Leads global communications and marketing for Warburg Pincus, covering the Americas region.

kerrie.cohen@warburgpincus.com

Alicia Levey· Venture Partner· San Francisco

Venture Partner in Versant's San Francisco office focused on investing and new company creation, with a background as a company creator, operator and dealmaker. She previously was President and COO of Pionyr Immunotherapeutics, held business development roles at Versant portfolio companies including Tempest Therapeutics and Inception Sciences, worked at Boston Consulting Group, and earned a Ph.D. in Cancer Biology from Stanford.

Kevin Grove· Venture Partner· Seattlein

Venture Partner focused on cardiometabolic disease, obesity and diabetes, with drug development and commercialization expertise. Joined Versant in July 2024 after nearly a decade at Novo Nordisk (where he founded its Seattle Obesity Research unit) and 20 years at Oregon Health Science University.

Monal Mehta· Venture Partner· New York Cityin

Monal Mehta is a Venture Partner in Versant's NYC office focused on early-stage healthcare companies. She was previously a Managing Director at Avidity Partners' Private Fund and served on several biotech boards, with prior roles in business development at Pfizer and consulting at Navigant. She holds a Ph.D. in Cancer Biology.

Peter Emtage· Venture Partner· San Francisco Bay Areain

Peter Emtage joined Versant Ventures as an Entrepreneur-in-Residence in October 2020 and became a Venture Partner in April 2021. He previously led cell therapy research at Kite Pharma (a Gilead company) and held senior scientific roles at Cell Design Labs and MedImmune, with over 20 years of drug development experience in oncology, autoimmunity, infectious diseases and inflammation.

Rami Hannoush· Venture Partner· San Diego and San Francisco Bay Areain

Venture partner focused on company creation, bringing both investment and drug discovery expertise. Previously a general partner at Mubadala Capital building its U.S. healthcare platform, co-founder and CEO of EpiBiologics, and a 16+ year Genentech R&D leader in oncology and immunology. Holds a Ph.D. in Chemistry from McGill with postdoctoral training at Harvard.

Richard Glynne· Venture Partner

Venture partner at Versant and president and CSO of Versant's Inception Sciences Discovery Engine, with expertise in developing and translating novel therapies. He joined Inception as CSO in 2018 after leading search and evaluation at Novartis and holding research leadership roles at the Genomics Institute of the Novartis Research Foundation, Eos Biotechnology, and Phenomix Corporation; he trained in immunology and genetics at ICRF London and Stanford (HHMI).

Tom Hudson· Venture Partner· Toronto

Venture partner supporting Versant's Frontier discovery engine in Toronto and contributing to new investments. He was previously SVP and chief scientific officer at AbbVie and the inaugural President and Scientific Director of the Ontario Institute for Cancer Research, and holds an M.D. from the University of Montreal.

Zach Sweeney· Venture Partner· San Francisco Bay Areain

Venture Partner at Versant with extensive experience leading drug discovery across small molecule, biotherapeutic, and technology platforms. Previously co-founded and served as CEO of Interline Therapeutics, was CSO of Denali Therapeutics, and held drug discovery leadership roles at Genentech, Roche, Novartis, and Revolution Medicines. He works with entrepreneurs to build new companies from early-stage science.

Omar El-Khalaf· Venture Partnerin

A Syrian-British entrepreneur and humanitarian who co-founded Empowerful, a charity initiative to empower students, in 2017.

Jeremy Caldwell· Venture Partner· San Diego, California𝕏

Markus Warmuth· Venture Partner· Cambridge, Massachusettsin 𝕏

Markus Warmuth serves as Chief Executive Officer at Monte Rosa Therapeutics and is a board member at Ventus Therapeutics. He is a physician scientist with experience in drug discovery, translational research, and clinical development across the pharmaceuticals industry.

Andrew Jefferson· Operating Partner

Operating Partner at Versant and COO of the firm's Ridgeline Discovery Engine, who joined in 2018 from Roche where he was VP of Business Development at Roche Molecular Solutions and previously Basel Site Head for Roche Partnering. He began his career in pharmaceutical manufacturing and worked in pharma business at Ciba-Geigy and Novartis in the UK, holding a BSc in Chemistry and an MBA.

Cathy Dring· Legal Counsel

Christine Mathews· Advisor

Ed Olhava· Scientist-in-Residence· San Francisco

Ed Olhava joined Versant in 2026 as a Scientist in Residence with over 20 years of experience leading small molecule drug discovery programs. He previously served as SVP of Preclinical Development at IFM Therapeutics, advised Third Rock Ventures, was the first medicinal chemist at Epizyme, and co-invented NINLARO at Millennium Pharmaceuticals.

Giorgio Ottaviani· Operating Partnerin

Operating Partner at Versant and SVP of Preclinical Development at the firm's Ridgeline Discovery Engine, with drug development expertise. He joined Ridgeline in 2018 from Roche, where he led DMPK-PD project leaders and headed non-clinical safety in Shanghai, and previously worked at Novartis and Merck-Serono. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Geneva and is a certified toxicologist (DABT).

Kenan Sagouspe· Portfolio Analyst

Kim Macniak· Controller· San Francisco Bay Areain

Lara Hoth· VP, Management Company Finance and Accounting

Lara Hoth is Versant's VP of management company finance and accounting, working with the CFO on the firm's financial and administrative operations across the U.S., Canada, and Switzerland. Before joining Versant in 2016 she spent six years at Novartis, held controller roles at two other companies, and began her career at PricewaterhouseCoopers; she holds a BA from UC Berkeley.

Laura Quock· CBO-in-Residence· San Francisco, Californiain

Laura joined Versant in June 2024 as a CBO-in-Residence, focused on strengthening business development across Versant's portfolio companies. She previously served as Senior Director of Corporate Development at Gilead, led the MiroBio acquisition, and held roles at Genentech, AbbVie, and Abbott Laboratories. She holds an MBA and M.S. in Chemical Engineering from UC Berkeley and a B.S. in Chemical Engineering from Purdue University.

Max Eisenberg· Chief Operating Officer and General Counsel· San Franciscoin

Max Eisenberg is COO and General Counsel at Versant, overseeing legal aspects of investment transactions, management company operations, fundraising, HR, and regulatory compliance. He previously served as the first General Counsel and Chief Compliance Officer at Polaris Partners.

Rich Van Doren· Chief Financial Officer

Rich Van Doren is the CFO of Versant Ventures with about 20 years of financial experience, previously serving as CFO of Samsara Biocapital and holding CFO/COO roles at Pacific Grove Capital, Marcato Capital, and Cannell Capital. He holds a B.S. in Finance from the University of San Francisco and a Graduate Certificate in Tax from Golden Gate University.

rvandoren@versantventures.com

Rick Dewey· Entrepreneur-in-Residence· Boston and New York Cityin

Rick Dewey joined Versant Ventures in 2024 as an Entrepreneur-in-Residence with over 15 years translating human genome insights into new medicines. He previously was Chief Scientific Officer of Foresite Labs and Head of Translational Genetics at Regeneron Genetics Center, and is a board-certified physician-scientist trained at Stanford.

Robin Praeger· Advisor· San Francisco, Californiain

Robin Praeger combined two decades as his firm's CFO (2000–2022) with investment leadership, bringing a CPA and Master of Taxation background that strengthens complex fund structuring and tax strategy.

Steve Edelson· VP, IR & Communications

Steve Edelson handles Versant's messaging, external and LP communications, and media relations. Before joining the firm, he spent 18 years at BioCentury Inc., rising from Staff Writer to Senior Editor and covering financial and emerging trends in the life science industry. He holds an M.S. in biotechnology and a B.A. in biochemistry from Northwestern University.

Vincent Ruland· Entrepreneur-in-Residence· Basel, Switzerlandin

Vincent Ruland joined Versant in August 2025 as an Entrepreneur-in-Residence in Basel, supporting existing portfolio companies and new opportunities in Europe and North America. He previously was SVP, Head of R&D Strategy, Portfolio and Operations at Bayer Pharmaceuticals, and is a physician-scientist trained in neuropathology with an M.D. from the University of Münster and an M.Phil. from the University of Cambridge.

Bryan Berg· CBO-in-Residence· Seattle, Washington, United Statesin 𝕏

Worked on early Stripe infrastructure and security; a partner at Standard Capital.

Didem Altop· Versant Venturesin 𝕏

General Partner at Treeo VC and founding managing director of Endeavor Turkey, where her work contributed to $2.7 billion in exits. She has launched six angel networks and advised the creation of seven VC funds.

didem@treeo.vc

Jeffrey M. Hurst· Entrepreneur in Residence· Dennis, Massachusetts, United Statesin

jeff@commonwealthvc.com

Mohan Menon· Entrepreneur in Residence· New York, New York, United Statesin

Managing Director at Richmond Global Ventures with three decades of company-building experience across four continents, Menon manages Smart City Technologies and is a Senior Advisor and Limited Partner at Meritage Funds. He previously held roles at Oracle, IBM, and J.D. Edwards.

mohan.menon@rglobal.com

Bill Link· Investor· Irvine, Californiain

Founder mafia

The Versant Ventures mafia →

17 people who came through Versant Ventures went on to found or lead other companies.

Kevin HykesOperating PartnerFounded Augmedics +2 Paul GraysonVenture PartnerFounded Radionetics +2 Erik T. EngelsonVenture PartnerFounded Medina Medical +1 Mike RosenbluthInvestment ProfessionalFounded Swing +1 Peter EmtageVenture PartnerFounded Santa Ana Bio Rami HannoushVenture PartnerFounded Epi Biologics Bryan BergCBO-in-ResidenceFounded Standard Capital Beckie RobertsonManaging DirectorFounded Egis Paul SekhriOperating PartnerFounded Vtvtherapeutics Brian AtwoodManaging DirectorFounded Cell Design Labs Marcelo BigalVenture PartnerFounded Ventus Therapeutics Markus WarmuthVenture PartnerFounded Monte Rosa Therapeutics

+ 5 more →

What they invest in

from 81 of 107 portfolio companies

Biotech ×65Healthtech ×50Medical Devices ×22Deep Tech ×15AI & Machine Learning ×12Digital Health ×5Hardware ×3Enterprise Software ×1

HQs:United States×66Switzerland×3Germany×1Denmark×1United Kingdom×1Mexico×1

Who they back

founder profiles across 8 portfolio companies

50%

solo founders

4 of 8 mapped founding teams

~3 yrs

old at investment

median across 8 dated deals

Founding team size:solo founder×42 founders×23 founders×14+ founders×1

Investments · 107 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 5 2024 · 6 2023 · 8 2022 · 6 2021 · 9 2020 · 5 2019 · 6 2018 · 8 2017 · 9 2016 · 1 2015 · 479 dated

Monte Rosa Therapeuticsmonterosatx.com in 𝕏NASDAQ: GLUESeries A · May 2020 · $33M✓ verified

Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.

AI & Machine LearningBiotechDeep TechHealthtechBoston, US

Markus Warmuth(M.D., Chief Executive Officer)in Sharon Townson(Ph.D., Chief Scientific Officer)in John Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)in Phil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in

Co-investorsAisling Capital HBM Partners New Enterprise Associates (NEA)Amzak Health Avoro Capital Advisors GV (Google Ventures)+4 more

Century Therapeutics, Inc.centurytx.com inNASDAQ: IPSCSeries A · Mar 2021 · $250M

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.

AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US

Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)in Brent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in

BoardToshikazu Ban(Director)

Board seat Carlo Rizzuto· per SEC Form D

Co-investorsLifeSci Venture Partners RA Capital Casdin Capital

Black Diamond Therapeutics, Incblackdiamondtherapeutics.comNASDAQ: BDTX

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)

Co-investorsLAV Lilly Asia Ventures New Enterprise Associates (NEA)Nextech Invest NSG Ventures RA Capital +4 more

Boundless Bioboundlessbio.com in 𝕏NASDAQ: BOLDApr 2021

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

Zachary D. Hornby(Executive Officer, Director)in Robert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in

Co-investorsARCH Venture Partners Nextech Invest RA Capital Wellington Management Alexandria City Hill Ventures +3 more

Contineum Therapeuticscontineum-tx.com inNASDAQ: CTNMSeries B · Dec 2019 · $32M

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.

BiotechHealthtech

Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)in Daniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in

Co-investorsHadean Ventures Red Tree Venture Samsara BioCapital Casdin Capital Franklin Templeton JJDC +1 more

LENZ Therapeutics, Inc.NASDAQ: LENZSeries A · Jun 2021 · $47M

Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

BiotechSouth San Francisco, US

Josh Lehrer(Executive Officer, Director)Katherine Stultz(Executive Officer)inPhilip Gutry(Executive Officer)Evert Schimmelpennink(Chief Executive Officer, President, Secretary, and Director)Daniel Chevallard(Chief Financial Officer)Shawn Olsson(Chief Commercial Officer)in

Co-investorsSamsara BioCapital

Passage Biopassagebio.com in 𝕏NASDAQ: PASGAug 2019 · $110M

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

Board Patrick Heron(Director)in Carl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFrazier Life Sciences Access Biotechnology Frazier Healthcare Partners Lilly Asia Ventures New Leaf Venture Partners OrbiMed +2 more

Bright Peak Therapeuticsbrightpeaktx.com inSeries A · Jun 2024 · $35M✓ verified

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Board seat Tom Woiwode Alex Mayweg· per SEC Form D

Co-investorsRA Capital Johnson & Johnson Innovation – JJDC Venrock Alexandria BlackRock Fidelity Investments +2 more

Lycia Therapeuticslyciatx.com in 𝕏Series A · Jun 2026 · $50M✓ verified

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)in Amy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in

Board seat Clare Ozawa· per SEC Form D

Co-investorsREDMILE HBM Healthcare Investments HBM Partners BAM Elevate Franklin Templeton Invus +5 more

AllRock Bioallrockbio.com in✓ verified

AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.

BiotechNatick, US

Catherine Pearce(CEO & Founder)inDHSc(Founder)Justin R Thompson(Founder)in

Co-investorsWestlake BioPartners Westlake Village BioPartners

Capsidacapsida.com in 𝕏✓ verified

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.

BiotechDeep TechDigital HealthMedical Devices

Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)in

Co-investorsWestlake Village BioPartners

Dualitas Therapeuticsdualitastx.com inJul 2025✓ verified

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in

Board Alicia Levey(Director)

Co-investorsQiming Venture Partners SV Health Investors Alexandria Dementia Discovery Fund Qiming Healthcare Qiming Venture Partners USA

Fablefabletherapeutics.com✓ verified

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.

BiotechHealthtechLongevity

Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)

Co-investorsMPM BioImpact DCVC Bio Lilly Asia Ventures DCVC (Data Collective)

Gate Biogatebio.comSeries A · Nov 2023 · $60M✓ verified

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical DevicesBrisbane, US

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)in Raman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)inJordi Mata-Fink, Ph.D.(Chief Executive Officer, Co-Founder)Raman Talwar, M.S.(Chief Technology Officer, Co-Founder)Pat Sharp, Ph.D.(Scientific Founder)

Co-investorsForbion Andreessen Horowitz ARCH Venture Partners Felicis Ventures GV (Google Ventures)

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)in

Co-investorsNovartis Venture Fund Sanofi Ventures Forbion

Iecureiecure.comSeries A · Sep 2021 · $50M✓ verified

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.

BiotechHealthtechMedical Devices

James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)inPaul Firuta(COO)inAlex Monteith(Chief Business Officer)David Garrett(CFO)in Gabriel M. Cohn(Chief Medical Officer)in

Co-investorsOrbiMed LYFE Capital

Lighthorsetxlighthorsetx.com✓ verified

Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.

AI & Machine LearningBiotechMedical Devices

Co-investorsTaiho Ventures, LLC AbbVie Mubadala Capital

Nested Therapeuticsnestedtx.com in 𝕏Seed · Jan 2022 · $35M✓ verified

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)in Philip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in

Co-investorsForesite Capital Sixty Degree Capital Cowen Healthcare Investments Goldman Sachs Section 32

Nexonexotx.com in✓ verified

Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches.

AI & Machine LearningBiotechDeep Tech

Andrew Phillips(Founder)John Athanosopoulos(Founder)Michael Kim(Founder)inRhamy Zeid(Founder)

Co-investorsNew Enterprise Associates (NEA)

Red Ridge Bioredridgebio.com✓ verified

RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases.

BiotechHealthtech

Bill Sellers(Scientific Founder and Director Cancer Program, Broad Institute)Stephen Yoder(President & CEO)in

Co-investorsNew Enterprise Associates (NEA)Sixty Degree Capital IDG Capital

Santa Ana Biosantaana.bio inSeries A · Feb 2023 · $43M✓ verified

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.

AI & Machine LearningBiotechHealthtechMedical DevicesAlameda, US

Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)in Ansuman Satpathy(Scientific Founder)in Newman Yeilding(Chief Medical Officer)in

Co-investorsAccess Biotechnology Andreessen Horowitz GV (Google Ventures)RTW Investments L.P.TPG Access Industries +1 more

Soteria Biotherapeutics, Inc.soteriabiotherapeutics.com inMay 2021✓ verified

Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.

BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)in Zachary Hill(Executive Officer, Director)in

BoardNisha Marathe(Director)David Allison(Director)in Keno Gutierrez(Director)in

Co-investors5AM Ventures Novartis Venture Fund Roche Venture Fund BioGeneration Ventures Westlake Village BioPartners

T-Knifet-knife.com inSeries A · Aug 2020 · $78M✓ verified

T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors.

BiotechHealthtechBerlin, DE

Elisa Kieback(Co-founder & Chief Technology Officer)inThomas Blankenstein(Scientific Founder)Thomas Soloway(Chief Executive Officer)Camille Landis(Chief Business Officer / Chief Financial Officer)inPeggy Sotiropoulou(Chief Scientific Officer)in

Co-investorsAndera Partners EQT Life Sciences RA Capital Sixty Degree Capital Fidelity Investments

Tentarixtentarix.com inSep 2023 · $35M✓ verified

Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.

BiotechDeep TechHealthtechMedical Devices

Board Srini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)

Co-investorsSamsara BioCapital Gilead Sciences

858 Therapeutics, Inc.8five8tx.comSeries A · Jul 2024 · $60M

858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways.

BiotechHealthtechSan Diego, US

Stafford Jeffrey(Executive Officer, Director)inJames Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)Joseph Leveque(Chief Medical Officer)

Board Ali Behbahani(Director)in

Board seat Clare Ozawa Monal Mehta Carlo Rizzuto· per SEC Form D

Co-investorsNew Enterprise Associates (NEA)Versant Venture Capital

Enable Injectionsenableinjections.com in 𝕏Dec 2025SEC filingmedium confidence

Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases.

BiotechHealthtechMedical DevicesCincinnati, US

Mike Hooven(Chairman, President and CEO)inTimothy Flaherty(Executive Officer)Simone Song(Director)Karen Robards(Director)Richard J D'Augustine(Director)Norman R. Weldon(Director)

Board seat Beckie Robertson· per SEC Form D · $30M raise · filed Jan 2026

Co-investorsAngel Physicians Fund CincyTech Lightship Capital Ohio Innovation Fund Magnetar AI Ventures

Jnana Therapeuticsjnanatx.com in 𝕏Series A · Dec 2017 · $50Macquired by Otsuka

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)Annie C. Chen(Director)

Board seat Carlo Rizzuto· per SEC Form D

Co-investorsAvalon BioVentures Bain Capital Life Sciences Pfizer Venture Investments RA Capital Pfizer Ventures Polaris Partners

Pandion Therapeuticspandiontx.comJan 2018acquired by Merck · Feb 2021 · $1.9BSEC filingmedium confidence

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)in Anthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seat Carlo Rizzuto· per SEC Form D · $80M raise · filed Apr 2020

Co-investorsAccess Biotechnology JDRF T1D Fund Mission Biocapital RA Capital SR One Capital Management Polaris Partners

Turnstone Biologicsturnstonebio.com inSeries A · Jan 2019 · $11M

BiotechNew York, US

Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)in Jane Henderson(Executive Officer)inStefan Larson(Director)Patrick Machado(Director)

Board seat Brad Bolzon Jerel Davis· per SEC Form D

Co-investorsBrace Pharma F-Prime Capital FACIT (Fight Against Cancer Innovation Trust)Foothill Ventures Venture Ontario OrbiMed +1 more

VENATORX PHARMACEUTICALS INCvenatorx.comJul 2017SEC filingmedium confidence

Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.

BiotechMalvern, US

Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)

Board seat Carlo Rizzuto· per SEC Form D · $47.1M raise · filed Nov 2018

Co-investorsAMR Action Fund BioAdvance Foresite Capital

Ventus Therapeuticsventustx.com inSeries A · Feb 2022 · $60M

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder)Daniel Koerwer(Executive Officer)in Michael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)

Board Josh Resnick(Director)in

Board seat Markus Warmuth Jerel Davis· per SEC Form D

Co-investorsAndreessen Horowitz GV (Google Ventures)RA Capital SoftBank Vision Fund Alexandria Biotechnology Value Fund +3 more

AcuFocus, Inc.acufocus.com

BiotechIrvine, US

Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)

BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)

Co-investorsEvidity Health Capital Flying L Partners Revelation Partners HEALTHCARE ROYALTY PARTNERS SV Life Sciences Versant Venture AIV Holdings

Advanced ICU Care inJul 2015

HealthtechSt Louis, US

Andrea M. Clegg(Executive Officer)Louis Silverman(Executive Officer, Director)

Board Barbara Lubash(Director)inMichael Mikolajczyk(Director)Timothy B. Petersen(Director)inDavid N. Schopp(Director)

Co-investorsArboretum Ventures

Akeroakerotx.com in 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Foresite Capital Frazier Life Sciences LifeSci Venture Partners Scion Life Sciences The Innovation Space +1 more

Altergalterg.com in 𝕏Aug 2018

AlterG develops anti-gravity treadmill systems using patented Differential Air Pressure technology to enable rehabilitation and athletic training.

HardwareHealthtechMedical DevicesSports TechFremont, US

Ross Jaffe(Director)Charles Remsberg(Executive Officer, Director)Antonio Mora(Director)David Grenewetzki(Director)Kevin Davidge(Executive Officer)Mark McKee(Director)

Anokionanokion.comSeries A · May 2014 · $38M

Co-investorsMPM BioImpact Vivo Capital

Antag Therapeuticsantagtherapeutics.com inSeries A · Dec 2024 · $84M

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in

Co-investorsBroadview Ventures Novo Holdings SR One Capital Management

Apreaaprea.com in 𝕏Dec 2025

Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.

BiotechDigital HealthMedical DevicesDoylestown, US

John P. Hamill(Executive Officer)in Oren Gilad(Chief Executive Officer, President)in

BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)

Co-investors5AM Ventures HealthCap Robin Hood Ventures Rosetta Capital Ltd.Soleus Capital

Baseline Therapeuticsbaseline-tx.com

Baseline is a biotech company focused on metabolism, obesity, incretins, and GLP-1-based strategies for substance use disorders, drawing on drug development and addiction medicine expertise.

BiotechDigital HealthHealthtech

Co-investorsVery Serious Ventures

Belharra Therapeuticsbelharratx.comSeries A · Jan 2023 · $50M

Belharra Therapeutics develops small molecule therapies aimed at previously undruggable protein targets across the proteome.

BiotechDeep Tech

BlueRockbluerocktx.com in

Blue Rock Therapeutics discovers and develops cell therapies to treat disease and improve patient outcomes.

AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US

Borealisbioborealisbio.com inSeries A · Aug 2024 · $150M

Borealis develops RNA medicines to treat kidney diseases.

BiotechDigital Health

Co-investorsWestlake Village BioPartners

Cimeio Therapeuticscimeio.comSeries A · Apr 2022 · $50M

Cimeio Therapeutics develops paired immunotherapies and gene-editing-based cell shielding technology that deplete diseased cells while protecting healthy hematopoietic stem cells from the same treatment.

BiotechDeep TechHealthtechBasel, CH

CRISPRcrisprtx.com in 𝕏Oct 2016

CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.

BiotechDeep TechHealthtechZug, CH

Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)in James R. Kasinger(General Counsel and Secretary)in Stephen Kennedy(Head of Technical Operations)in Megan Wherry Menner(Head of Human Resources)in Naimish Patel(Chief Medical Officer)in

Co-investorsAvoro Capital Advisors CLI Ventures Khosla Ventures New Enterprise Associates (NEA)SR One Capital Management Wellington Management +2 more

Enterprise Therapeuticsenterprisetherapeutics.com in 𝕏

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

John Ford(Co-founder)in Martin Gosling(Founder)in

Co-investorsEpidarex Capital Novartis Venture Fund Forbion IP Group Panakes Partners

Epix Therapeuticsinacquired by Medtronic · Jan 2019 · $316M

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8VC CWRU Technology Ventures Elevate Ventures Menlo Ventures Oak Investment Partners Pfizer Venture Investments+5 more

ForteBiofortebio.comOct 2005 · $17.3Macquired by Pall

Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.

Co-investorsLatterell Venture Partners MPM BioImpact OrbiMed The Vertical Group

Gritstone biogritstonebio.comSeries A · Oct 2015 · $100MAcquired

Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.

BiotechHealthtechSan Carlos, US

Andrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)

Co-investorsFrazier Life Sciences GV (Google Ventures)Sofinnova Ventures The Column Group REDMILE

Gritstone Oncologygritstoneoncology.com inSep 2017

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsBay City Capital GV (Google Ventures)LAV Lilly Asia Ventures Alexandria Frazier Healthcare Partners +1 more

Helicore Biopharmahelicore.comSeries A · Jan 2025 · $65M

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.

BiotechHealthtechSouthbury, US

Kevin Russ(Chief Executive Officer)in Peter DiLaura(Chief Executive Officer and Board Director)inWaters Kellogg(Director)Lucas B. Turner(Director)Joshua Dotson(Director)Holger Koehler(Director)

Co-investorsLongitude Capital OrbiMed Wellington Management

Immune Designimmunedesign.com 𝕏Jul 2010 · $32MAcquired

Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.

BiotechHealthtechMedical DevicesSeattle, US

David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in

Co-investorsAisling Capital Atlas Venture HM Venture Partners OUP (Osage University Partners)Sanderling Ventures Sanofi Ventures +4 more

Inari Medical Inc.inarimedical.com inMar 2018 · $27M

Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.

HardwareHealthtechMedical DevicesIrvine, US

William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)

BoardDonald Milder(Director)Kirk Nielsen(Director)in Jonathan Root(Director)inBrian Cox(Director)

Co-investorsGilde Healthcare US Venture Partners Vensana Capital

Jecure Therapeutics inJul 2018

BiotechSan Diego, US

Jeffrey Stafford, Ph.D.(Executive Officer, Director)James Veal, Ph.D.(Executive Officer)Ariel Feldstein, M.D.(Director)

BoardBradley Bolzon, Ph.D.(Director)Thomas Woiwode, Ph.D.(Director)

Kate Therapeuticskatetherapeutics.com in 𝕏Series A · Jun 2023 · $51M

BiotechSan Diego, US

Kevin Forrest, Ph.D.(Executive Officer, Director)

BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)

Co-investorsOUP (Osage University Partners)Westlake Village BioPartners Kleiner Perkins

Lenzlenz-tx.com in 𝕏Mar 2023 · $83.5M

LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.

BiotechHealthtechMedical DevicesSan Diego, US

James McCollum(Co-founder, Board Member)Eef Schimmelpennink inEvert Schimmelpennink(President and CEO)

Co-investorsAlpha Wave Global RA Capital Raptor Group RTW Investments L.P.Sectoral Asset Management

Metaventionmetavention.com inDec 2017

Metavention is developing a treatment that targets the sympathetic nervous system to disrupt overactive nerves believed to contribute to high blood pressure and other metabolic diseases.

BiotechHealthtechMedical DevicesEden Prairie, US

Bobak Azamian(Executive Officer, Director)Tony Vrba(Executive Officer)Kevin Hykes(Executive Officer, Director)Kirk Nielsen(Director)in

Co-investorsSanderling Ventures New Enterprise Associates (NEA)Vensana Capital

Microfabrica inDec 2011

Van Nuys, US

Eric Miller(Executive Officer, Director)inMichael Lockard(Executive Officer)in

BoardWarren Packard(Director)Kevin Wasserstein(Director)Eugene Chen(Director)Michael Sweeney(Director)

Co-investorsChevron Technology Ventures Draper Fisher Jurvetson (DFJ)

Nouscomnouscom.comNov 2017

Immunotherapy company developing NOUS-209 for the prevention of Lynch syndrome-associated cancers.

Co-investors5AM Ventures Andera Partners Angelini Ventures CDP Venture Capital Indaco Venture Partners M Ventures +6 more

Novasys Medicalnovasysmedical.comMay 2008 · $49.5M

HealthtechNewark, US

Scott Cramer(Executive Officer, Director)in

BoardGlenn Reicin(Director)Richard Lin(Director)Douglas Kelly(Director)Rebecca Robertson(Director)Randy Lindholm(Director)

Co-investorsAscension Ventures GBS Venture Partners Ltd.Invesco

Nuvairanuvaira.com in 𝕏Feb 2019 · $79M

Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD).

HardwareHealthtechMedical DevicesMinneapolis, US

Martin Mayse(Founder)inSteve Dimmer(Founder)in Dennis Wahr(President & CEO)in Lisa Flaherty(Chief Strategy Officer)in Steve Sathre(Vice President of Finance)inSteve Paidosh(Vice President of Operations)

Co-investorsWindham Capital Partners Endeavour Vision Lightstone Ventures Morgenthaler Qiming Venture Partners Richard King Mellon Foundation +2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Aset Therapeutics Chinook Therapeutics U.S Concerto Healthcare Firefly Bio, Inc.Graphite Bio, Inc.Jengu Therapeutics, Inc.March Therapeutics, Inc.Mistral Therapeutics Nexo Therapeutics, Inc.Pep2Tango Therapeutics Presbyopia Therapies Benvenue MedicalBorealisCapsida BiotherapeuticsChinook TherapeuticsFireflyForSight VISION5Inception 4 and 5Inception IBD Intuity MedicalKolmLaunchpad Therapeutics, Inc.Matterhorn BiosciencesNeliNeoVistaNorthern BiologicsNovira TherapeuticsOyster Point PharmaceuticalsQuanticelQuentisRepare TherapeuticsRespicardia Sequent MedicalSixPeaks BioTentarix BiotherapeuticsVectivBioVector BioPharmaZyga Technology

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 16

7 IPOs · 9 acquisitions · showing 13

Monte Rosa TherapeuticsNASDAQ: GLUECentury Therapeutics, Inc.NASDAQ: IPSCBlack Diamond Therapeutics, IncNASDAQ: BDTXBoundless BioNASDAQ: BOLDContineum TherapeuticsNASDAQ: CTNMLENZ Therapeutics, Inc.NASDAQ: LENZPassage BioNASDAQ: PASGJnana Therapeuticsacq. by OtsukaPandion Therapeuticsacq. by MerckEpix Therapeuticsacq. by MedtronicForteBioacq. by PallNovira Therapeuticsacq. by Johnson & Johnson (Janssen)Vividion Therapeuticsacq. by Bayer

Portfolio news

latest coverage across their companies

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - BioSpace

Aprea · biospace.com · Sep 10, 2026

CRISPR Therapeutics, Inc. - MassBio

CRISPR · massbio.org · Sep 6, 2026

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026

Contineum Therapeutics schedules a Sept. 15 fireside chat at 5:35 p.m.

Contineum Therapeutics · stocktitan.net · Aug 25, 2026

Lycia Therapeutics Raises $75M in Series D Funding

Lycia Therapeutics · finsmes.com · Jun 29, 2026

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer

Antag Therapeutics · globenewswire.com · May 21, 2026

Granite Bio Debuts With $100 Million of Capital - BioSpace

Granite Bio · biospace.com · Nov 5, 2025

Fund performance · per public LP disclosures · 3

as of Sep 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Versant Venture VII, L.P.LPs: San Diego City Employees' Retirement System	2018	—	9.6%	1.50x	0.37x
Versant Venture VI, L.P.LPs: San Diego City Employees' Retirement System	2017	—	16.0%	1.81x	1.16x
Versant Venture Capital II, L.PLPs: The Regents of the University of California, Richard King Mellon Foundation	2001	—	4.2%	1.33x	1.33x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings · 4

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
LENZ Therapeutics, Inc.	29.0%	$17.00	Jun 2021	$276M
Monte Rosa Therapeutics	19.6%	$19.00	Jun 2021	$166M
Passage Bio	10.8%	$18.00	Feb 2020	$85.2M
Contineum Therapeutics	22.7%	$16.00	Apr 2024	$85.1M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

2 insider ownership filings (Forms 3/4/5)

Files 13F institutional holdings reports · latest Aug 2026

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Versant Ventures made?: Versant Ventures has 107 tracked investments, 16 of which have exited, including 9 dated in the last 24 months.
What stage does Versant Ventures invest at?: Versant Ventures invests at the Seed, Series A, Series B, Series C, Late Stage stages.
What is Versant Ventures's typical check size?: Versant Ventures typically writes checks of $250K – $5M.
What sectors does Versant Ventures focus on?: Versant Ventures focuses on Biotech, Healthtech.
Where is Versant Ventures located?: Versant Ventures is headquartered in San Francisco, US.
Does Versant Ventures lead rounds?: Versant Ventures typically participates in rounds rather than leading them.
Who does Versant Ventures co-invest with?: Versant Ventures most often shares deals with GV (Google Ventures), New Enterprise Associates (NEA), RA Capital, among 52 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Carlo Rizzuto, Partner at Versant Ventures, on NewYorkBIO's #VirtualBreakfastSeries

NewYorkBIO Video Channel · Carlo Rizzuto

Carlo Rizzuto (Versant Ventures) | Videos & Movies on Vimeo

Columbia Tech Ventures · Carlo Rizzuto · vimeo.com

Images

Co-investors · 44

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 13

Black Diamond Therapeutics, Inc Monte Rosa Therapeutics 858 Therapeutics, Inc.Aset Therapeutics CRISPR Launchpad Therapeutics, Inc.Metavention Nexo Nexo Therapeutics, Inc.Oyster Point Pharma, Inc.Red Ridge Bio Stablix Tempest Therapeutics

$200K – $40M

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 11

Black Diamond Therapeutics, Inc Boundless Bio Century Therapeutics, Inc.Aset Therapeutics Bright Peak Therapeutics Jnana Therapeutics Lenz Pandion Therapeutics T-Knife Ventus AI Ventus Therapeutics

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 7

Monte Rosa Therapeutics Gate Bio Gritstone bio Gritstone Oncology Santa Ana Bio Ventus AI Ventus Therapeutics

$250K – $50M

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 7

Passage Bio ForteBio Helicore Biopharma Iecure Lycia Therapeutics Turnstone BiologicsRepare Therapeutics

$1M – $75M

Samsara BioCapital

Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.

Both backed · 7

Contineum Therapeutics LENZ Therapeutics, Inc.Chinook Therapeutics U.S Rayze Bio TentarixChinook TherapeuticsGraphite Bio, Inc.

Casdin Capital

Casdin Capital is an investment firm focused on the life sciences, investing across healthcare, biotechnology, synthetic biology, and related technology.

Both backed · 6

Century Therapeutics, Inc.Contineum Therapeutics Monte Rosa Therapeutics Ventus AI Ventus Therapeutics Vividion Therapeutics

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 5

Fable Firefly Bio, Inc.ForteBio NeoVistaAnokion

$1M – $15M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 4

Gate Bio Santa Ana Bio Ventus AI Ventus Therapeutics

$500K – $50M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 4

Aprea Nouscom Novira Therapeutics Soteria Biotherapeutics, Inc.

$100K – $4M

Domain Associates

Domain Associates is a venture capital firm founded in 1985 that invests in life sciences companies. The firm operates as a limited liability company.

Both backed · 4

Benvenue Medical Sebacia Sequent Medical Zyga Technology

$200K – $15M

Nextech Invest

Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.

Both backed · 4

Black Diamond Therapeutics, Inc Boundless Bio Aset Therapeutics Vividion Therapeutics

$648K – $3.2M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 3

Boundless Bio Gate Bio Vividion Therapeutics

$50K – $250M

▶32 more co-investors

OUP (Osage University Partners)SR One Capital Management Forbion The Column Group Vivo Capital Avoro Capital Advisors F-Prime Capital Venrock Polaris Partners EQT Life Sciences Sanofi Ventures venBio Partners Abingworth Aisling Capital Frazier Healthcare Partners Andera Partners HBM Partners Kleiner Perkins Canaan Partners Access Industries New Leaf Venture Partners Amplitude Venture Capital Unknown Ventures General Atlantic Wildcat Venture Partners Earlybird Venture Capital Highland Capital Partners Ysios Capital Volition Capital KohFounders Elo Health Buff Gold Ventures

Firms observed investing alongside Versant Ventures, from public investor directories. Shared companies are the overlap with Versant Ventures's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

EDB Investments

EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.

Founders Fund

Founders Fund is a venture capital firm that backs technology companies building transformative products.

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

$30M